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Abstract 
Small molecules that can target human cancers have been highly sought to increase the 
anticancer efficacy, the present work describes the design and synthesis of novel series of 
five quinuclidinone derivatives (2a-2e). Their anticancer activities were investigated 
against breast cancer cells MCF-7, MDA-MB-231 breast cancer cells harboring mutant 
p53 and normal breast counterpart MCF-12a. Derivative 2e reduced proliferation of MCF-
7 and MCF-12a while it has no effect on MDA-MB-231. Derivative 2e induced apoptosis 
in MCF-7 cells which is further confirmed by TUNEL assay and it reduced the percentage 
of cell in G2/M phase as confirmed by increased expression of cyclin B and reduced 
expression of cyclin D1. Derivative 2e reduced expression levels of Mdm2, Akt and 
ERK1/2 by and increased expression level of p53. Moreover, the apoptosis induction by 2e 
was also inhibited by PFT-α as evidenced by non-significant induction of apoptosis after 
treatment of MCF-7 cells with both derivative 2e and PFT-α. In addition, docking study 
reveals that derivative 2e has a binding pattern close to the pattern observed in the structure 
of the lead fragment 5,6-dimethoxy-2-methylbenzothiazole bound to T-p53C-Y220C. The 
above findings demonstrate that derivative 2e induces apoptosis in MCF-7 cells via 
targeting p53 which merits further development. 
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1. Introduction 
Cancer today accounts for more deaths worldwide than tuberculosis, HIV, and malaria 
combined. Breast cancer is the most common cancer among women. It will afflict an 
estimated 9.1 million women in poorer countries over the next decade. Of the 5 million 
women expected to die from breast cancer in the next decade, 70 percent will live in low- 
and middle-income countries
1
. 
Breast cancer is a heterogeneous disease and different breast cancer subtypes can be 
identified based on gene expression profiling. Current breast cancer therapies, based on 
Selective Estrogen Receptor Modulators (SERMs), such as tamoxifen or aromatase 
inhibitors, can be unsuccessful due to intrinsic or acquired resistance to these therapies
2
. 
Consequently, discovery and development of new class of anticancer drugs are urgently 
needed to combat the growing threat of high mortality rate. 
 
Quinuclidinones belongs to the group of bicyclic bridgehead lactams and are highly twisted. 
This twisted nature decreases the delocalization effect, increasing the basicity of the nitrogen 
so that it often behaves more like an amine than as a typical planar amide. This might 
increase selectivity and affinity of a pharmacophore element towards different receptor 
binding sites
3
. Literature survey revealed that The molecule 3-quinuclidinone is an attractive 
candidate in medicinal chemistry as it constitute the building block of wide range of many 
pharmacologically active compounds having anticancer effect
4
, antihistamine-
bronchodilating activity
5
,  nicotinic receptors inhibitory activity
6
, anti Alzheimer's effect
7
. In 
addition, it has been reported that quinuclidine moiety constitute the basic skeleton for many 
synthetic pharmacologically active existing drugs for example; palonosetron and azasetron 
as 5-HT3 receptor blockers
8
, solifenacin and cevimeline as muscarinic receptor antagonists
9
,  
and quinupramine as a tricyclic antidepressant
10
 (Figure 1). 
Moreover, in a previous publication - in our laboratoy - quinuclidinone demonstrated an 
excellent scaffold for novel anti-cancer agents with improved safety profile. With the intact 
carbonyl group of quinuclidinone, more potent derivatives against lung carcinoma cells 
were reported
11
. In addition, novel quinuclidinone analogs that induce cytotoxicity in human 
non-small lung carcinoma cell line (H1299) null for p53, a tumor suppressor protein, have 
previously been reported
12
. In continuation on our research program, it was also confirmed 
that  other quinuclidinone derivatives induce apoptosis in human breast cancer cells via 
reduced expression level of Bcl-2,Bcl-XL and increased mitochondrial apoptotic pathways 
by activating the release of cytochrome C
13
. The conventional view of p53-mediated 
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apoptosis has emphasized its role as a transcription factor
14
. The p53 protein been thought to 
be the molecular target of  Pifithrin-alpha (PFT) which has been widely used as a ubiquitous 
and reversible inhibitor of p53 and p53 mediated apoptosis
15
. The pharmacological rescue of 
inactive p53 may therefore represent an attractive therapeutic strategy. Pifithrin-alpha (PFT) 
is an inhibitor of p53 and is considered to be useful for therapeutic suppression to protect 
against various genotoxic agents 
16
. Several reports have shown that Pifithrin-alpha (PFT) 
blocks the p53-mediated activation of autophagy caused by stress-inducing agents 17. PFT 
has been validated as a useful p53 inhibitor for the elucidation of p53 functions in 
experimental studies.The pharmacological salvage of inactive p53 may represent an 
attractive therapeutic tool. Pifithrin-alpha (PFT) is an inhibitor of p53 and is considered to be 
useful for therapeutic suppression in order to reduce cancer treatment side effects and to 
protect against various genotoxic agents
16
. Several reports have shown that PFT blocks the 
p53-mediated apoptotic effect caused by chemical agents
17
.  In summary, PFT has been 
validated as a useful p53 inhibitor for investigating p53 functions in experimental studies. 
In view of the above mentioned results and as a continuation of our research on 
Quinuclidinones in an attempt to identify new lead compounds that might be of value for 
future development as new class of anticancer agents, a series of novel quinuclidinone based 
amines (2a-2e) were synthesized. The structures of title compounds were well supported by 
spectroscopic data and elemental analysis. The target compounds comprise some 
pharmacophoric elements which influence the biological activity of the molecules, such as 
the aryl ring as hydrophobic binding site, the nitrogen of the secondary amine as electron 
donor, additional NH group as hydrogen bonding domain. To understand the mechanism of 
action and the effects on cancer biology, we evaluated the effect of the most promising 
compounds on cell cycle, apoptosis and the tumor suppressor p53. A molecular docking 
study was also performed for the most active compounds in a trial to investigate the possible 
mode of action of these compounds. 
 
 
2. Results and discussion 
2.1. Chemistry 
The synthetic strategies to obtain the target compounds are depicted in Scheme 1.  The 
key starting material 2-methylenequinuclidine-3-one hydrochloride 1 was refluxed with 
phenyl and 4-nitrophenyl hydrazine in ethanol in the presence of sodium bicarbonate to  
yield the corresponding N-[(3-oxo-quinuclidin-2yl)methyl]-N'-phenylhydrazine 2a and 
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N-[(3-oxo-quinuclidin-2yl)methyl]-N'-4-nitrophenylhydrazine 2b, respectively. 
Reacting the starting compound 1  with different amines in the presence of sodium 
bicarbonate  yielded secondary amine substituted 2-methylenequinuclidine-3-one 
namely; 2-[(4-chloroanilino)methyl]-3-quinuclidone 2c
18
, 2-[(4-bromoanilino)methyl]-
3-quinuclidone 2d
18
, and 2-[(1H-benzo[d]imidazol-2-ylamino)methyl]-3-quinuclidone 
2e.  The synthesized compounds were supported by spectroscopic data.  The 
1
H-NMR 
(ppm) of the resulted compounds were characterized by the presence of multiplet 
allocated for NCHCH2,  doublet or multiplet for the aromatic ring-Hs, multiplet for the 
benzimidazole C4,7-Hs,  multiplet for the benzimidazole C5,6-Hs at the expected range 
of δ –ppm scale and a D2O exchangeable singlet for the NH. 
Biological evaluation 
2.2.1. Quinuclidinone derivatives 2e reduced cell proliferation and induced apoptosis in 
breast cancer cells 
Previously our laboratory reported novel quinuclidinone derivatives which reduced 
proliferation of lung cancer cell lines. In this report, we managed to synthesize and 
confirm structures of these derivatives (2a-2e). We investigated the effect of the 
proposed five quinuclidinone derivatives against breast cancer cells MCF-7 and MDA-
MB-231 to determine if the potent derivative is working in p53 dependent or 
independent mechanism. We first showed the impact of these 5 derivatives on 
proliferations of breast cancer cells (MCF-7 and MDA-MB-231). Our data indicated 
that 10 µM quinuclidinone  derivatives 2e was potent in decreasing cell viability in 
MCF-7 breast cancer cells (20%) compared to control untreated cells (Figure2A). The 
dose response curve was constructed to determine IC50 for the potent derivative 2e 
(Figure 2B). We used 4 µM of derivative 2e and also examined its cytotoxcity against 
normal breast epithelial cells (MCF-12a) and results are represented in Figure2C.  To 
determine if the decreased cells viability is linked to apoptosis, ELISA assay was 
performed to detect histone release from apoptotic cells, revealing that 4μM of 2e  
treatment induced apoptosis in  MCF-7 cells compared with non-treated control 
(P<0.05) (Figure2D). The results were confirmed by immunohistochemical analysis 
using TUNEL assay which showed the formation of more TUNEL positive cells in 
MCF-7 up on treatment of cells with derivative 2e (Figure2E). 
We treated MDA-MB-231 with derivative 2e in order to determine if this derivative is 
working via p53 dependent or p53 independent mechanism. Our data revealed that our 
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derivatives 2e did not affects the cell viability in MDA-MB-231 cells and it did not 
induce any significant increase in apoptosis under the same conditions (Figure 2F,G).  
 
2.2.2. Quinuclidinone derivatives 2e modulates G2/M checkpoint 
MCF-7 cells were treated with 4 μM of 2e and harvested after 24 h and showed a 
significant decrease in the percent of G2/M cells (10%) compared to control group 
(30%) (Figure 3A). The abrogation of G2/M checkpoint was confirmed by the 
increased expression levels of cyclin B (2-fold increase) and reduction of cyclin D 
levels (4-fold decrease) (Figure 3B).  
 
2.2.3. Quinuclidinone derivatives 2e modifies apoptotic signals and increase p53 
expression  
Apoptosis occurs due to an imbalance between pro and anti-apoptotic proteins.  
Derivative 2e reduced expression levels of Mdm2, Akt and ERK1/2 by (4, 3 and 2 fold 
respectively) and  increased expression level of p53 (2.5-fold) (Figure 4A). We next 
examined the role of p53 transcription by using a p53 transcriptional inhibitor, PFT-α, a 
specific inhibitor of p53 transcriptional targets. As shown in Figure3A, PFT-α  
inhibited the up-regulation of p53 and it suppressed activation of p53 targets Mdm2, 
Akt and Erk1/2 (Figure 4B). Moreover, the apoptosis induction by 2e was also inhibited 
by PFT-α as evidenced by non-significant induction of apoptosis after treatment of 
MCF-7 cells with both 2e and PFT-α (Figure 4C). 
From the above study it  was appeared that compound 2e is the most active deivative. It 
induced apoptosis in  MCF-7 and increasesd expression of tumor suppressor p53. The 
increased activity of compound 2e is related to the pharmacophoric elements which 
influence its biological activity such as NH group of benzimidazole ring which forms 
an additional hydrogen bonding domain. In addition,  benzimidazole ring displayed 
hydrophobic interactions with the hydrophobic binding site in the receptor. 
 
2.2. Molecular Modeling 
The docking study was carried out using the enzyme parameters obtained from the 
crystallographic structure of T-p53C-Y220C (a stable variant of p53 core domain with 
the Y220C mutation) bound to the lead fragment 5,6-dimethoxy-2-methylbenzothiazole 
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(PDB ID: 2X0W)
19
. The docking simulation for the ligand was carried out using 
molecular operating environment (MOE) software supplied by the Chemical 
Computing Group, Inc., Montréal Canada
20
. 
The structure of lead fragment 5,6-dimethoxy-2-methylbenzothiazole bound to T-p53C-
Y220C showed that the molecule sits in an upright position within the mutation-
induced cavity (Figure5). The thiazole nitrogen is within hydrogen-bonding distance of 
the hydroxyl group of Thr150. The methoxy moieties of the molecule sit at the bottom 
of the cavity in close proximity to Cys220.  
Figure 6 shows the binding mode of compound 2e docked and minimized in the 
mutation induced cavity of T-p53C-Y220C. In this case, hydrogen bond is observed 
between the nitrogen of benzimidazole and the hydroxyl group of Thr150. Hydrogen 
bond is also observed between NH group and oxygen of Thr150.   
In addition, compound 2e displayed hydrophobic interactions with the same amino 
acids Val147, Pro151, Cys 220 and Glu221 bound to the lead fragment.  
The docking study shows that compound 2e has a binding pattern which is close to the 
pattern observed in the structure of the lead fragment 5,6-dimethoxy-2-
methylbenzothiazole bound to T-p53C-Y220C. Compound 2e forms hydrogen bonds 
with the same residue (Thr150) as that observed in the structure of the lead fragment 
with T-p53C-Y220C. This may account for increased activity recorded for compound 
2e. 
3.  Conclusion 
Apoptosis occurs due to an imbalance between pro and anti-apoptotic proteins. 
Derivative 2e reduced proliferation and induced apoptosis in MCF-7 cells with no 
impact on MDA-MB-231.  The tumor suppressor p53 exerts its biological effect by 
regulating transcription of numerous downstream target genes involved in cell cycle 
arrest, apoptosis and DNA repair, In order to better understand the mechanisms of 
action of compounds that target mutant p53, it is important to determine whether they 
can directly bind with mutant p53 or proteins involved in the process of mutant p53 
reactivation or depletion. Additionally, it reduced expression levels of Mdm2, Akt and 
ERK1/2  and increased expression level of p53. We next  examined  the  role  of  p53  
transcription  by  using  a  p53  transcriptional inhibitor, PFT-α, a specific inhibitor of 
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p53 transcriptional targets. PFT-α inhibited the up-regulation of p53 and it suppressed 
activation of p53 targets Mdm2, Akt and Erk1/2. Moreover, the apoptosis induction by 
derivative 2e was also inhibited by PFT-α as evidenced by non-significant induction of 
apoptosis after treatment of MCF-7 cells with both 2e and PFT-α. Additionally, 
derivative 2e forms hydrogen bonds with the same residue (Thr150) as that observed in 
the structure of the lead fragment with T-p53C-Y220C. This may account for increased 
expression levels of p53 recorded for derivative 2e.  Our results suggest that derivative 
2e might be promising anticancer agent in breast cancer cells via targeting p53. 
4. Experimental 
4.1. Chemistry 
Melting points were determined in open-glass capillaries on SMP10–Barloworld 
Scientific melting point apparatus and are uncorrected. The infrared (IR) spectra were 
recorded on Perkin-Elmer 1430 infrared spectrophotometer using the KBr palate 
technique. 
1
H spectra were run on a Varian spectrometer (300 MHz), Faculty of 
Science, Cairo University using tetramethylsilane (TMS) as the internal standard and 
DMSO-d6 as the solvent (Chemical shifts in δ, ppm). Splitting patterns were designated 
as follows: s: singlet; d: doublet; t: triplet; q: quartet and m: multiplet. Microanalyses 
were performed at the at the Microanalytical unit, Faculty of Science, Cairo University 
and the found values were within ±0.4% of the theoretical values. 
 
4.1.1. General procedure for preparation of compounds 2a-e 
 
A mixture of 2-methylenequinuclidine-3-one hydrochloride 1 (0.174 g, 0.001 mole), 
sodium bicarbonate (0.084 g, 0.001 mole) and phenyl hydrazine, 4-nitrophenyl 
hydrazine or the appropriate amine (0.001 mole) in ethanol (5 ml) was heated under 
reflux for 12-18 h. The solvent was evaporated under reduced pressure and the 
remaining solid was triturated with water, filtered, dried and crystallized from 
methanol. 
 
4.1.1.1. N-[(3-Oxo-quinuclidin-2yl)methyl]-N'-phenylhydrazine 2a 
Yield: 80%, mp: 145-148 
o
C. IR (cm
-1
):  3150, 3110 (NH); 1730 (C=O). 
1
H-NMR (δ 
ppm):1.68-1.93 (m, 4H, 2 CH2); 2.38 (bs, 1H, bridgehead); 2.62-2.82 (m, 4H, 2 NCH2); 
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3.12-3.17 (m, 3H, NCHCH2), 4.32 (s, 1H, NH, D2O exchangeable); 7.01-7.49 (m, 5H, 
aromatic H). Anal.Calcd for C14H19N3O (245.32): C, 68.54; H, 7.81; N, 17.13. Found: 
C, 68.78; H, 8.05; N, 16.89. 
 
4.1.1.2. N-[(3-oxo-quinuclidin-2yl)methyl]-N'-4-nitrophenylhydrazine 2b 
Yield: 88%, mp: 170-172 
o
C. IR (cm
-1
):  3145, 3120 (NH); 1730 (C=O). 
1
H-NMR (δ 
ppm):1.48-1.86 (m, 4H, 2 CH2); 2.37 (bs, 1H, bridgehead); 2.57-2.78 (m, 4H, 2 NCH2); 
2.80-2.89 (m, 3H, NCHCH2); 4.28 (s, 1H, NH, D2O exchangeable); 7.36 (d, 2H, J = 8.5 
Hz,  aromatic H); 8.11 (d, 2H, J = 8.5 Hz, aromatic H).  Anal.Calcd for C14H18N4O3 
(290.32): C, 57.92; H, 6.25; N, 19.30. Found: C, 58.13; H, 6.41; N, 19.59. 
 
4.1.1.3. 2-[(4-Chloroanilino)methyl]-3-quinuclidone 2c 
Yield: 80%, mp: 126-128 
o
C [reported 127-131
 o
C]
18
.  
4.1.1.4. 2-[(4-Bromoanilino)methyl]-3-quinuclidone 2d 
Yield: 85%, mp: 131-135 
o
C [reported 132-134
 o
C]
18
.  
4.1.1.5. 2-[(1H-Benzo[d]imidazol-2-ylamino)methyl]-3-quinuclidone 2e 
Yield: 86%, mp: 160-162 
o
C. IR (cm
-1
): 3236, 3128 (NH); 1730 (C=O). 
1
H-NMR (δ 
ppm):1.77-1.90 (m, 4H, 2 CH2); 2.26 (bs, 1H, bridgehead); 2.70-2.91 (m, 4H, 2 NCH2); 
2.93-3.23 (m, 3H, NCHCH2); 6.05 (s, 1H, NH, D2O exchangeable); 6.79--6.81 (m, 2H, 
benzimidazole-C5,6-H); 7.04-7.07 (m, 2H, benzimidazole-C4,7-H). Anal.Calcd for 
C15H18N4O (270.33): C, 66.64; H, 6.71; N, 20.73. Found: C, 67.05; H, 6.84; N, 20.39. 
 
4.2. Biological evaluation 
4.2.1. Cell culture and Compound treatment 
MCF-7, breast cancer cells with wild type p53 geneand MDA-MB-231 breast cells 
have a mutant p53  were purchased from ATCC (USA). MCF-7 cells were maintained 
in Dulbecco’s modified essential media (DMEM) (Gibco, California, USA) 
supplemented with 10% Fetal Bovine Serum, 100 Units/ml penicillin and 100 μg/ml 
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streptomycin at 37
o
C in a 5% CO2 atmosphere (Gibco, California, USA). MCF-12a 
cells were maintained in DMEM/F-12 media (Gibco, California, USA) supplemented 
with 10% FBS, 100 Units/mL penicillin, 100 μg/mL streptomycin, insulin (1.2 g/L), 
transferrin (0.001 mg/mL), EGF (20ng/μL) and hydrocortisone (500 ng/mL) at 37°C in 
a 5% CO2 atmosphere. The synthesized compounds were prepared in 10μM 
concentration and dissolved in suitable media.PFTα (1-(4-methylphenyl)-2-(4,5,6,7-
tetrahydro-2-imino-3(2H)benzothiazolyl)ethanone hydrobromide) was purchased from 
Cayman Chemical Company (Ann Arbor, Michigan USA). 
 
4.2.2.  Methyl tetrazolium (MTT) bromide mitochondrial activity assay  
Cell viability was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay as described previously(ATCC, Manassas, VA 
USA).  Briefly, 4000- 5000 cells/well in 100 µL of medium were seeded into 96-well 
plates. After 24 h incubation at 37 °C, the culture media were removed and replaced 
with fresh media containing the test compounds (100 μM). The cells were incubated for 
another 24 h then, 10 µL of 5 mg/ mL MTT reagent was added to each well and 
incubated for 4 h at 37 °C. After incubation, 100 µL of detergent reagent was added to 
each well to dissolve the formazan crystals. The absorbance was determined at 
570 nmusing Spectra Max Plus. Each assay was performed in triplicate and the 
experiment was repeated three times and standard deviation was determined. To 
determine the IC50 of compound 2e, the assay was conducted using different 
concentrations of compound 2e and the average 50% inhibitory concentration (IC50) 
was determined from the dose response curve. 
4.2.3. Enzyme linked immunosorbent apoptosis assay 
Cells were seeded at a density of 2 X 10
4
/ well in a 96- well plate and incubated for 24 
hours. Media were changed to media containing compound 2e (4 μM). Cells were then 
incubated for 24 hours.  An ELISA assay was performed using Cell Death Detection 
ELISA
PLUS
 kit (Roche-Applied Science, Indianapolis, USA) that measures histone 
release from fragmented DNA in apoptosing cells. Briefly, cells were lysed with 200-
μL lysis buffer for 30 min at room temperature. The lysate was centrifuged at 200 g for 
10 min.  150 μL of supernatant was collected, of which 20 μL was incubated with anti-
histone biotin and anti-DNA peroxidase at room temperature for 2 h. After washing 
with incubation buffer three times, 100 μL of substrate solution (2,2`azino-di(3-
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ethylbenzthiazolin-sulphuric acid) was added to each well and incubated for 15-20 min 
at room temperature. The absorbance was measured using an ELISA reader (Spectra 
Max Plus) at 405 nm.  Each assay was done in triplicate and the standard deviation was 
determined. 
4.2.4. TUNEL assay 
For in situ detection of apoptotic cells, TUNEL (terminal-deoxynucleotidyl transferase 
meditated nick end labeling) assay was performed using DeadEnd
TM
fluorimetric tunnel 
system (Promega, USA). Cells were cultured on 4-chamber slides (VWR, USA) at a 
density of 2 X10
4
 cells/ chamber. After treatment with 4μM of compound 2e, cells were 
washed with phosphate buffer saline (PBS) and fixed by incubation in 4% 
paraformaldehyde (PFA) for 20 min at 4 
o
C, then permeabilized with 0.05% triton X-
100 for 5 min at 4 
o
C. The fixed cells were then incubated with digoxigenin-conjugated 
dUTP in terminal deoxynucleotide transferase recombinant (rTdT)-catalyzed reaction 
and nucleotide mixture for 60 min at 37 
o
C in a humidified atmosphere and then 
immersed in stop/wash buffer for 15 min at room temperature. Cells were then washed 
with PBS to remove unincorporated fluorescein-12-dUTP. After washing with PBS, 
cells were incubated in 1μg/ml 2-(4-amidinophenyl)-6-indole 
carbamidinedihydrochloride (DAPI) and fluorescinisothiocyanate (FITC) solution for 
15 min in dark (data not shown). Cells were observed with fluorescence microscopy 
(RT slider Spot, Diagnostic Instruments, Inc) and photographed at 100X magnification. 
4.2.5. Cell cycle analysis 
Cells were seeded at a density of 3-5 X 10
5
/ 10 cm plateand incubated for 24 h before 
treatment. Media was changed to media containing 4 μM of compound 2e, 24 hours 
later, cells were harvested by trypsinization. The cells were washed with PBS and fixed 
with ice-cold 70 % ethanol while vortexing. Finally, the cells were washed and 
resuspended in PBS containing 5 μg/mL RNase A (Sigma, St. Louis, MO USA) and 50 
μg/mL propidium iodide (Sigma, St. Louis, MO USA) for analysis.  Cell cycle analysis 
was performed using FACScan Flow Cytometer (Becton Dickson) according to the 
manufacturer’s protocol. Windows multiple document interfaces (WinMDI) software 
was used to calculate the cell-cycle phase distribution from the resultant DNA 
histogram, and expressed as a percentage of cells in the G0/G1 and G2/M phases. The 
apoptotic cells were identified on the DNA histogram as a subdiploid peak. 
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4.2.6.  Determination of pro-apoptotic, anti-apoptotic proteins by Western blotting 
analysis 
Total protein was extracted from cells treated with 4 µM of compound 2e and untreated 
cells using lysis buffer (10 mMTrisHCl pH 7.5, 1 mM EDTA, 1% triton X-100, 150 
mMNaCl, 1 mMdithiothretol, 10% glycerol, 0.2 mMphenylmethysulphonyl fluoride 
and protease inhibitors) for 30-50 min on ice. The extracts were centrifuged at 13,000 
rpm for 15 min at 4°C to remove cell debris. Folin Lowry (Pierce, USA) protein assay 
was used to determine the protein concentration in the cell lysates. Proteins were 
resolved by electrophoresis on 8-10% sodium dodecyl sulphate – polyacrylamide gel 
loading equal amount of proteins per lane. The resolved proteins were transferred to 
polyvinylidene difluoride (PVDF) membrane and then probed with primary antibody 
against the protein of interest prepared in 5% milk/PBS-T. The membrane was washed 
using Phosphate-buffered Saline with Tween 20 (PBS-T) and then appropriate 
secondary antibody conjugated to horseradish peroxidase (HRP) was used for 
visualization of the bands using ECL chemiluminescence kit (GE, USA).  AntiP53 anti-
Mdm2, anti-ERK1/2, anti- Akt, anti-cyclinD1 and anti-cyclin B were purchased from 
SantaCruz, USA. MEK1 and SP600125 were purchased from Santa cruz, USA.  Pixel 
density of the proteins studied was calculated using Image J, version 1.41o, NIH. The 
obtained values were first normalized to loading control β-actin) and folds increase was 
measured by normalizing to the control (0 hr) value. At least two independent 
experiments were performed. 
 
 
4.3. Molecular modeling studies 
Computer-assisted simulated docking experiments were carried out under an 
MMFF94X forcefield using Molecular Operating Environment (MOE Dock 2009) 
software, Chemical Computing Group, Montréal, Canada. 
The coordinates from the X-ray crystal structure of T-p53C-Y220C used in this 
simulation were obtained from the Protein Data Bank (PDB ID: 2X0W), where the 
active site is bound to 5,6-dimethoxy-2-methylbenzothiazole. The ligand molecule was 
constructed using the builder module and were energy minimized. The active site of T-
p53C-Y220C was generated using the MOE-Alpha Site Finder, and then the ligand was 
docked within this active site using the MOE Dock. The lowest energy conformation 
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was selected and the ligand interactions (hydrogen bonding and hydrophobic 
interaction) with T-p53C-Y220C were determined. 
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Figure captions 
 
Fig. 1 structures of some quinuclidine based drugs.  
Fig. 2 Impact of derivative 2e on proliferation and apoptosis in breast cancer cells. 
Cell proliferation assay was performed to detect living cells. MCF-7 cells were treated 
with 10 µM of 2e for 24 h (A). Dose response curve was done to determine the IC50 for 
the potent derivative 2e (B). Cell viability was determined for both MCF-7 cells and MCF-
12 by using 4 µM of derivative 2e (C). Determination of apoptosis in MCF-7 cells and 
MCF-12 cells by 4 µM 2e and 24 h duration interval (D). Each data point is the mean of 
three independent experiments and expressed as M±SD. Induction of apoptosis 
represents absorbance at 405 nm. TUNEL assay was used to confirm induction of 
apoptosis between treated and non-treated cells. MCF-7 cells were treated with 4 µM 2e 
for 24 h and induction of apoptosis was confirmed by appearance of TUNEL positive 
cells (E). Cell proliferation assay was performed to detect living cells.  MDA-MB-231 
were treated with 4 µM of 2e for 24 h (F). Apoptosis was determined in MDA-MB-231 
cells by 4 µM 2e and 24 h duration interval (G) 
Fig. 3 Derivative 2e reduced cells in G2/M checkpoint in MCF-7. The % of cell cycle 
phases was determined in MCF-7 cells after treatment with 4 µM drugs of drug 2e for 
24 h (A). Cells were treated with derivative 2e, total protein was extracted and used for 
Western blotting analysis to determine the differences in cyclin D and cyclin B 
expression levels between treated and non-treated cells at the same condition (B). β-
actin was used as loading control protein 
Fig.4 Inhibition of p53 signaling by derivative 2e. MCF-7 Cells were treated with 
derivative 2e, total protein was extracted and used for Western blotting analysis to 
determine the differences in Mdm2, p53, Akt and ERk1/2 expression levels between 
treated and non-treated cells at the same condition (A). β-actin was used also adding 
control protein. MCF-7 cells were with 10 µM PFT-α for 1 hr and then treated with 
100 µM derivative 2e for additional 24 hrs and cells then harvested to extract same 
proteins mention under same condition (B). induction of apoptosis was determined as 
indicated by reading Abs at 405 nm for control, treated cells with derivative 2e and 
cells treated with both derivative 2e and 10 µM PFT-α. Each data point is the mean 
of three independent experiments and expressed as M±SD. induction of apoptosis 
was determined as indicated by reading Abs at 405 nm for control, treated cells with 
derivative 2e and cells treated with both derivative 2e and 15 µM PFT-α. Each data 
point is the mean of three independent experiments and expressed as M±SD 
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Fig. 5. Binding mode of lead fragment in the mutation-induced cavity of T-p53C-
Y220C using MOE software 
Fig. 6. Binding mode of compound 2e docked and minimized in the mutation-induced 
cavity of T-p53C-Y220C using MOE software 
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Novel Quinuclidinone Derivatives Induced Apoptosis in Human Breast Cancer 
via Targeting P53 
Ahmed Malki , Rasha Y. Elbayaa , Omnia Ali, Ahmed  Sultan, Amal M. Youssef
  
 
 The present work describes the design and synthesis of novel series of five 
quinuclidinone derivatives (2a-2e).Their anticancer activities were investigated against 
breast cancer cells MCF-7, MDA-MB-231 breast cancer cells harboring mutant p53 
and normal breast counterpart MCF-12a.  Derivative 2e reduced proliferation of MCF-
7 and MCD-12a while it has no effect on MDA-MB-231.Derivative 2e induced 
apoptosis in MCF-7 cells which is further confirmed by TUNEL assay and it reduced 
the percentage of cell in G2/M phase as confirmed by increased expression of cyclin B 
and reduced expression of cyclinD1.Derivative 2e reduced expression levels of Mdm2, 
Akt and ERK1/2 by and increased expression  
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